Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunology

Set Alert for Immunology

Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs

The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.

China Commercial

All Systems Go At Almirall To Enter Tough Atopic Dermatitis Market With Ebglyss

Following a positive opinion from the CHMP, the Spanish company is hoping to launch its challenger to Dupixent in the EU before the end of the year.

Immune Disorders Business Strategies

A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE

The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.

FDA Inflammation

Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

Companies Cancer

Biogen’s Latest Leadership Change Hints At Immunology Ambitions

New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.

Companies Leadership

Stallergenes Greer Gets Hold Of Nestlé’s Palforzia For Peanuts

Nestlé has finally divested the peanut allergy business acquired in 2019 to much fanfare after the treatment spectacularly failed to live up to its blockbuster potential.

Deals Strategy

Ventus Enters NLRP3 Inhibitor Race With Parkinson’s Candidate

Tricky drug development challenges have held back the NLRP3 inhibitor field for decades but Ventus and its many rivals believe the class can deliver on its huge potential, from Parkinson’s disease to NASH and arthritis.

Neurology Clinical Trials

Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter

The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.

Financing Immune Disorders

Novartis’s Remibrutinib Succeeds In Pivotal CSU Trials With Promise Of Liver Safety

The major’s BTK inhibitor candidate, remibrutinib, met the primary and secondary endpoints of two Phase III trials in chronic spontaneous urticaria, with unproblematic liver function results so far, suggesting it may avoid pitfalls faced by rivals.

Clinical Trials Dermatology

Galapagos Could Give Up On Jyseleca Over JAK Class Woes

New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”

Sales & Earnings Business Strategies

Galapagos Sees Global Market For Point-Of-Care CAR-T But Is Still On M&A Trail

Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.

Cancer Immune Disorders

Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

French pharma gets global rights at the start of Phase II for the US biotech’s preclinical program for inhibiting the STAT6 protein in respiratory and dermatologic disorders.

Deals Business Strategies
See All
UsernamePublicRestriction

Register